Paid Clinical Trials in Edmonds, WA
As of September 2026, 82 paid clinical trials are recruiting in Edmonds, Washington. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Edmonds offers studies at sites including Swedish Cancer Institute-Edmonds for conditions such as Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm, Melanoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Edmonds
Trials by drug in Edmonds
Filter results
82 clinical trials
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Analysis of Human Movement With Assistive Devices
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Family Communications After Genetic Testing
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Top Research Study Locations in Edmonds
Researchers run research studies in Edmonds, WA at 12 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Swedish Cancer Institute-Edmonds | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm | 59 |
| Swedish Cancer Institute - Edmonds | Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung, Breast Cancer | 6 |
| Swedish Cancer Institute | Advanced Non-Small-Cell Lung Cancer, Advanced Solid Tumors, EGFR P-Loop and Alpha C-Helix Compressing | 3 |
| Swedish Cancer Institute - Edmonds Campus | Breast Cancer, Carcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer | 3 |
| Ascentage Investigative | CML, CML, Chronic Phase, Chronic Myeloid Leukemia | 1 |
| Eye Associates Northwest - Edmonds Clinic | Advanced/Metastatic Urothelial Cancer, Urothelial Cancer, Urothelial Carcinoma | 1 |
| Local Institution - 0491 | Untreated, Unresectable, or Metastatic Colorectal Cancer | 1 |
| Local Institution - 0515 | Non-small Cell Lung Cancer | 1 |
| Orthocare Innovations, LLC | Limb Loss, Limb Paralysis, Limb Weakness | 1 |
| Swedish Cancer Institute Edmonds | Colorectal Neoplasms | 1 |
| Swedish Cancer Institute Edmonds Campus | Carcinoma, Non-Small Cell Lung, Cutaneous Squamous Cell Cancer, Esophageal Adenocarcinoma | 1 |
| Swedish Medical Center Edmonds | Central Line Associated Blood Stream Infections (CLABSI) | 1 |
Active & Upcoming Studies in Edmonds (2026)
Recruiting trials in Edmonds grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (67 active studies)
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) · Phase 2 · National Cancer Institute (NCI)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations · Phase 3 · SWOG Cancer Research Network
Common conditions studied in Edmonds
- Acute Myeloid Leukemia (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Malignant Solid Neoplasm (4 active studies)
- Melanoma (4 active studies)
- Breast Cancer (3 active studies)
- Chronic Lymphocytic Leukemia (3 active studies)
Leading research sponsors in Edmonds
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Edmonds?
There are approximately 82 recruiting clinical trials in Edmonds, Washington listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Edmonds pay participants?
Most recruiting trials in Edmonds compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Edmonds?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Edmonds?
The most common conditions under active study in Edmonds include Acute Myeloid Leukemia (6), Anatomic Stage II Breast Cancer AJCC v8 (4), Malignant Solid Neoplasm (4), Melanoma (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Edmonds?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Edmonds on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Edmonds?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Edmonds?
Recruiting research sites in Edmonds include Swedish Cancer Institute-Edmonds, Swedish Cancer Institute - Edmonds, Swedish Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Edmonds right now?
The largest active categories in Edmonds are Cancer & tumors (67). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.